Project Grant RF1AG079890
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$2.2M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
The Oregon Health & Science University was awarded a three-year, $3.956 million project grant from the National Institutes of Health National Institute on Aging under the Aging Research program (CFDA 93.866). The grant will support research into the role of G protein-coupled receptor 39 in age-related vascular cognitive impairment. Specifically, the university researchers will test the hypothesis that endothelial-pericyte EET/GPR39 signaling plays a protective role against aging- and small...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $471,885 to Oregon Health & Science University (OHSU) for a 2-year research project studying the mechanisms underlying brain vascular endothelial cell (BVEC) disruption following vascular brain injury (VBI). The overarching goal is to understand how the glycosaminoglycan hyaluronan (HA) protects BVECs from ferroptosis, a form of programmed cell death, and how the enzyme CEMIP may...
The National Institute on Aging (NIA) awarded a $471,635 Project Grant (CFDA 93.866 - Aging Research) to the Arizona Veterans Research And Education Foundation, a non-profit research organization, to conduct studies on the role of the peptide Medin in vascular aging and its relationship to dementia disorders. Key products and services to be delivered under this grant include: Genome-wide CRISPR/Cas9 screening in endothelial cells to identify genes and biological pathways involved in...
This $1,120,805 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853), will support research to investigate how prior SARS-CoV-2 infection may increase the risk of vascular contributions to cognitive impairment and dementia (VCID). The research aims to: Determine how prior SARS-CoV-2 infection influences blood-brain barrier...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...
This $844,931 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the role of the VGF protein in the comorbidity of major depressive disorder (MDD) and late-onset Alzheimer's disease (LOAD). The primary awardee, the Icahn School of Medicine at Mount Sinai, will characterize novel binding interactions between VGF-derived neuropeptides and receptors such as neuropilins and FGFR2, evaluating their functional roles and downstream...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $801,476 is focused on studying cerebrovascular reactivity (CVR) as a potential biomarker for vascular contributions to cognitive impairment and dementia (VCID) in patients with CADASIL, a rare genetic form of small vessel disease. The University of Wisconsin-Madison is the prime awardee and will leverage an existing longitudinal cohort of 400 CADASIL patients with NOTCH3 gene...
The National Institute on Aging (NIA) awarded a $1,783,700.00 Project Grant under the Aging Research program (CFDA 93.866) to the University of Illinois to develop novel blood-brain barrier permeable multimodal imaging agents for the diagnosis of neurodegenerative diseases, with a focus on Alzheimer's disease and related dementias. The 3-year grant aims to employ organic and inorganic chemical design principles to generate diagnostic agents capable of detecting protein aggregation,...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of the NOX2 enzyme in mediating the brain dysfunction associated with Alzheimer's disease (AD). The $842,175 award, effective December 15, 2024 through November 30, 2029, will allow the J. David Gladstone Institutes, a non-profit biomedical research organization, to explore the potential of a novel NOX2 antagonist (GSK2795039) in mitigating AD-related pathologies such...
The National Institute on Aging (NIA) awarded a $514,862 Project Grant (CFDA 93.866 - Aging Research) to Neuroindx, a for-profit, woman-owned small business, to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and related disorders (ADRDs). The goal of the project is to create an in vitro assay that can replicate key features of the neuronal microtubule microenvironment and use kinesin-based readouts to measure the ability of...